DexCom (DXCM) announced the FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for people over the age of 18 with diabetes in the United States.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom initiated with an Outperform at Mizuho
- DexCom names Jon Coleman as chief commercial officer
- Positive Outlook for Dexcom: Buy Rating Backed by Promising CGM Technology and Market Growth Potential
- Insulet expands Omnipod 5 to four more International markets
- Optimistic Buy Rating for Dexcom Despite FDA Warning Letter